Ruvidar Demonstrates 7 Year Complete Response #BiotechInvesting #BiotechInvestor #BiotechStocks #MicroCap #SmallCapStocks #Chemicals #Pharmaceutical #Biotechnology #HealthCare #Medical #Pharmaceuticals #Technology #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing

Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that a patient enrolled in the Phase Ib Non-Muscle Invasive Bladder Cancer...


http://dlvr.it/TK0lcG

Comments

Popular posts from this blog

ICEBERG Financial Announces New Fintech Product and Pre-Launch Institutional Contract #Banking #FinancialServices

Aurora Solar Technologies Corporate Update #AACTF #ACU.CA #ACU.V #AlternativeEnergy #AuroraSolarTech #CleanEnergy #CorporateUpdate #Energy #Investing #OTC #OTCMarkets #OTCStocks #RenewableEnergy #SmallCaps #Solar #TSXV

Coelacanth Announces Q3 2023 Financial and Operating Results #CEI.CA #CEI.V #CEIEF #Earnings #Investing #OTC #OTCMarkets #OTCStocks #Oil #OilAndGas #QuarterlyResults #Results #SmallCaps #TSXV